Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma by Hjortland, Geir O et al.
CASE REPORT Open Access
Genome wide single cell analysis of
chemotherapy resistant metastatic cells in a case
of gastroesophageal adenocarcinoma
Geir Olav Hjortland1,2*, Leonardo A Meza-Zepeda2, Klaus Beiske3, Anne H Ree1, Siri Tveito2, Hanne Hoifodt2,
Per J Bohler4, Knut H Hole5, Ola Myklebost2, Oystein Fodstad2, Sigbjorn Smeland1 and Eivind Hovig2,6,7
Abstract
Background: Metastatic progression due to development or enrichment of therapy-resistant tumor cells is
eventually lethal. Molecular characterization of such chemotherapy resistant tumor cell clones may identify markers
responsible for malignant progression and potential targets for new treatment. Here, in a case of stage IV
adenocarcinoma of the gastroesophageal junction, we report the successful genome wide analysis using array
comparative genomic hybridization (CGH) of DNA from only fourteen tumor cells using a bead-based single cell
selection method from a bone metastasis progressing during chemotherapy.
Case presentation: In a case of metastatic adenocarcinoma of the gastroesophageal junction, the progression of
bone metastasis was observed during a chemotherapy regimen of epirubicin, oxaliplatin and capecitabine, whereas
lung-, liver and lymph node metastases as well as the primary tumor were regressing. A bone marrow aspirate
sampled at the site of progressing metastasis in the right iliac bone was performed, and single cell molecular
analysis using array-CGH of Epithelial Specific Antigen (ESA)-positive metastatic cells, and revealed two distinct
regions of amplification, 12p12.1 and 17q12-q21.2 amplicons, containing the KRAS (12p) and ERBB2 (HER2/NEU)
(17q) oncogenes. Further intrapatient tumor heterogeneity of these highlighted gene copy number changes was
analyzed by fluorescence in situ hybridization (FISH) in all available primary and metastatic tumor biopsies, and
ErbB2 protein expression was investigated by immunohistochemistry.
ERBB2 was heterogeneously amplified by FISH analysis in the primary tumor, as well as liver and bone metastasis,
but homogenously amplified in biopsy specimens from a progressing bone metastasis after three initial cycles of
chemotherapy, indicating a possible enrichment of erbB2 positive tumor cells in the progressing bone marrow
metastasis during chemotherapy. A similar amplification profile was detected for wild-type KRAS, although more
heterogeneously expressed in the bone metastasis progressing on chemotherapy. Correspondingly, the erbB2
protein was found heterogeneously expressed by immunohistochemical staining of the primary tumor of the
gastroesophageal junction, while negative in liver and bone metastases, but after three initial cycles of palliative
chemotherapy with epirubicin, oxaliplatin and capecetabine, the representative bone metastasis stained strongly
positive for erbB2.
Conclusion: Global analysis of genetic aberrations, as illustrated by performing array-CGH analysis on genomic
DNA from only a few selected tumor cells of interest sampled from a progressing bone metastasis, can identify
relevant therapeutic targets and genetic aberrations involved in malignant progression, thus emphasizing the
importance and feasibility of this powerful tool on the road to more personalized cancer therapies in the future.
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Background
The incidence of adenocarcinomas of the gastric cardia,
the gastroesophageal junction (GEJ) and esophagus has
had a sharp rise in the past few decades, in particular
among white males in the United States and western Eur-
ope, whereas the incidence of gastric cancer of the corpus
or pyloric region has declined in many western countries
[1-3]. In contrast to squamous cell carcinomas of the eso-
phagus, which are strongly associated to alcohol and
tobacco consumption, adenocarcinomas of the lower eso-
phagus, GEJ and proximal stomach are typically associated
with factors like Barrett’s esophagus, gastroesophageal
reflux, asthma medications, cholecystectomy, and obesity
[4-9]. The dismal outcome of these patients, often due to
the advanced disease stage at diagnosis, underlines the
need for new treatment options, as well as better under-
standing of the biology of the disease. Improving therapy
of metastatic gastroesophageal adenocarcinoma is war-
ranted. A landmark study in this regard was the recently
published randomized phase III ToGA study [10], estab-
lishing c-erbB2 (HER-2/neu) as a target for therapy in
advanced gastric and gastroesophageal junction cancer,
with clinically significant improved overall survival for
patients treated with trastuzumab in a first line regimen of
5-fluorouracil/capecitabine and cisplatin. As gastric cancer
reveals more heterogeneity in the expression of erbB2
than breast cancer, a modified scoring system for gastric
cancer was agreed upon at an international consensus
meeting [11], and used by the panel of pathologists in the
ToGA study. Patients having tumors with high expression
of erbB2 (IHC3+) and ERBB2 FISH positive revealed a
particular benefit of the trastuzumab treatment, whereas
the benefit was less for the patients with lower expression
levels of erbB2 or with negative FISH. However, in light of
these exciting data, the clinical significance of intrapatient
erbB2 heterogeneity in metastatic gastroesophageal cancer
at diagnosis and during ongoing chemotherapy is less well
known. Different metastatic tumor cell clones may show
different sensitivity to chemotherapy, or change during
disease progression, due to metastatic evolution [12]. In
this case of adenocarcinoma of the gastroesophageal junc-
tion, we examined the erbB2 expression in multiple meta-
static lesions as well as the interlesional heterogeneity in
response to chemotherapy. The chemotherapy resistant
metastatic cells in a progressing metastatic bone lesion
after the initial cycles of chemotherapy were analyzed gen-
ome-wide by screening of DNA copy number changes to
identify oncogenic aberrations and potential targets of
therapy.
Case presentation
A 35-year old white male, non-smoker, was admitted to
hospital as he had experienced increasing pain in the
upper part of the abdomen, and his general practitioner
had discovered elevated levels of serum transaminases.
He had no previous medical record, except appendect-
omy. During the previous 2-3 months, he had lost 3-4
kgs of weight and had experienced episodes of night
sweat, but no fever, and a varying degree of edema in
both legs. On physical examination, he appeared slim,
ECOG (Eastern Cooperative Oncology Group) perfor-
mance status 0. The abdomen was normally configured,
but the liver was palpable 3 cm below the costal ridge.
He had a slight edema of both legs and ultrasonic exam-
ination showed thrombosis of deep veins distally of the
popliteal fossae in both lower extremities. Colonoscopy
was normal, but gastroscopy revealed a non-stenotic
small polypous lesion in the gastroesophageal junction,
34 cm from the dental lining and 3 cm above the linea
dentata. CT scans showed multiple metastases (Figure
1) in both lungs and several pathologically enlarged
lymph nodes up to 2 cm in diameter in the mediasti-
num, both lung hili, the liver hilus and in the retroperi-
toneal compartment. There were multiple metastases in
all liver segments, and the left side of the distal esopha-
geal wall had a thickened appearance. MRI of the head,
spine and pelvis revealed bone metastases scattered in
several locations of the spine and pelvis. Laboratory
investigations showed blood values within reference lim-
its of differentiated blood cell counts, electrolytes, creati-
nine, urea, glucose, bilirubin and albumin. There were
elevated serum levels of lactate dehydrogenase (568 U/L;
normal range < 205 U/L), alkaline phosphatase (650 U/
L; normal range < 105 U/L), alanine aminotransferase
(174 U/L; normal range 10-70 U/L), carcinoembryonic
antigen (CEA;1833 μg/L), CA-125 (2747 kU/L) and
MUC-1 (115 kU/L).
Biopsies from the gastroesophageal tumor and metas-
tases in the liver and bone marrow were sampled. The
histopathology revealed a moderately differentiated ade-
nocarcinoma, with glandular structures formed by atypi-
cal columnar epithelium, with unevenly and aberrantly
distributed chromatin structures within the cell nuclei,
and tumor infiltration of normal squamous epithelium.
Immunohistochemical staining was positive for cytoker-
atin (CK) 7, caudal related homeobox-2 (CDX-2), CEA,
and negative for CK20, prostate specific antigen, synap-
tophysin, chromogranin A, and thyroid transcription
factor TTF-1, thus supporting the diagnosis of a neo-
plasm of the gastroesophageal junction as the primary
tumor.
After the first three cycles of palliative chemotherapy
with epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2
intravenously every third week and continuous oral
administration of capecitabine (Xeloda®) 625 mg/m2
twice daily (EOX), thoracic and abdominal CT scans
showed reduction of lung, liver and lymph node metas-
tases (Figure 1). Serum CEA was reduced from 2685 μg/
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L at onset of chemotherapy to 76 μg/L. In contrast,
metastases in the pelvic skeleton and spine had pro-
gressed (Figure 2), A bone marrow aspirate and a new
biopsy was sampled at this point from the right iliac
bone for molecular analysis of the tumor cells and a sec-
ond histological analysis. Fourteen cells rosetted with
anti-ESA coated magnetic beads (Dynal® Magnetic
Beads, Invitrogen) were picked using a motorized micro-
scope device fitted with a glass capillary (CellPick)[13].
Genomic DNA from these cells was amplified using the
Genomplex Single cell WGA kit (Invitrogen) (Figure 3).
To identify genomic aberrations, array comparative
genomic hybridization (CGH) was performed using a 1
Mb resolution genomic microarray essentially as
described previously [14]. Genome-wide analysis of copy
number changes identified two distinct regions of ampli-
fication, 12p12.1 and 17q12-q21.2, both approximately
3.3 Mb in size. A number of genes are known to be
located within the amplified regions, among them KRAS
(12p) and ERBB2 (HER2/NEU) (17q). Amplified DNA
from the same cells was also subjected to KRAS exon-1
mutation detection [15], and no mutation was identified.
As also seen in many gastric adenocarcinomas, immu-
nohistochemical analysis of erbB2 protein expression in
the biopsies from the primary gastroesophageal tumor
showed heterogeneity, with both negative (1+) cells next
to nests of positive cells (3+) (Figure 4). The erbB2
immunohistochemical scoring was performed as
described previously [11]. In biopsies from pelvic bone
and liver metastases, immunohistochemical staining
showed tumor cells negative (1+) for the erbB2 protein,
but after the first three cycles of EOX, mainly positive
erbB2 (3+) expressing tumor cells were seen in the bone
marrow. Amplification of the ERBB2 and KRAS genes
were analyzed by FISH, applying commercial probes for
ERBB2, centromere 12 and 17 (Abbott Molecular Inc.,
Des Plaines, IL, USA) and two BAC-clones spanning the
chromosome 12p12.1 region (RP11-583L24 and RP11-
707G18) for KRAS on the biopsies mentioned above. In
the primary tumor, we found that both ERBB2 and
KRAS were heterogeneously amplified (Figure 5). For
ERBB2 analysis, 270 tumor cell nuclei were evaluated
and 66 (24.4%) showed amplification with an average
ERBB2/centromere 17 ratio of 6,1. FISH analysis of
KRAS and centromere 12 revealed 124 amplified among
450 investigated cells (27.6%) with an average KRAS/
centromere 12 ratio of 4,8. Both ERBB2- and KRAS-
amplified cells were heterogeneously distributed between
non-amplified cells, either as small clusters or as single
cells. In the liver metastasis, both KRAS and ERBB2
were heterogeneously amplified, but in the bone metas-
tasis we found no ERBB2 or KRAS amplification. How-
ever, in the bone metastasis biopsy sampled after three
courses of EOX, ERBB2 was homogenously amplified.
Here, 92 of 120 (76.7%) evaluated tumor cell nuclei
scored positive with an average ERBB2/Centromere 17
ratio of 7,6. Due to the limited amount of metastatic
tumor cells in deeper sections, only 22 nuclei were avail-
able for the FISH analysis of KRAS and 8 of these dis-
played amplification (Figure 5).
Figure 1 CT scans before and after the first three cycles of
chemotherapy. (A) Chest CT scan at the time of diagnosis
revealing multiple metastases in both lungs, and (B) the
corresponding image after chemotherapy. (C) Coronal section from
an abdominal CT scan at the time of diagnosis showing multiple
liver metastases (three are marked with arrows) and also the tumor
of the left wall of the gastroesophageal junction (arrowhead). (D)
Corresponding section as C in an abdominal CT scan after
chemotherapy showing decreased size of liver metastasis.
Figure 2 CT scans, coronal sections, showing growth of bone metastasis at different time points during the progression of the
disease. (A) CT scan at the time of diagnosis, (B) after 9 weeks (C) after 16 weeks, and (D) after 24 weeks.
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Figure 3 Tumor cells from bone marrow aspirate and the results from array CGH analysis performed on such tumor cells. (A) An ESA
positive tumor cell rosetted with magnetic beads conjugated with an anti-ESA antibody. (B) Array CGH data of 14 ESA-positive tumor cells
displaying low resolution of amplification levels of all 23 chromosomes extended. (C) A close-up of the 12p amplicon, and (D) close-up of the
17q amplified locus.
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Chemotherapy was continued, and after two more
cycles of EOX, CT scan evaluation showed a further
reduction of the lung, liver and lymph nodes metastases,
serum CEA was further reduced to 39 μg/L. CT evalua-
tion also showed bone metastasis progressing steadily
and unaffected of the palliative chemotherapy given.
Due to increased pain in his lower back and the pelvic
area, the patient received palliative radiotherapy to 30
Gy in two weeks to the affected area. The EOX che-
motherapy was continued and he received zoledronic
acid due to lytic bone lesions. Two additional cycles of
EOX was given, but due to general disease progression
the treatment was discontinued. He experienced
increased pain, had decreased appetite and had lost an
additional 5 kgs of weight. Shortly after, he was
admitted to hospital because of acute neurological
symptoms with pareses and paralysis of left cranial
nerves (i.e. the trigeminal (V) and abducens (VI) nerves).
An MRI scan revealed multiple meningeal metastatic
deposits and disseminated pathologic lesions in the
bone marrow of the scull, facial bones and spine. High-
dose glucocorticosteroid treatment relieved the symp-
toms, and he was given palliative radiotherapy (to 30 Gy
in two weeks) towards the whole brain, including the
meninges and base of the skull. His health condition did
not allow further treatment with any second-line che-
motherapy regimen, but a regimen of trastuzumab
monotherapy (4 mg/kg i.v. followed by 2 mg/kg week i.
v.) was initiated. Six weeks thereafter he was admitted
to the local hospital because of acute respiratory distress
and pneumonia. One week after the hospital admission,
the patient deteriorated and died.
Discussion
A main challenge in metastatic cancer treatment is the
development or enrichment of therapy-resistant tumor
cells. In this young patient with stage IV gastroesopha-
geal adenocarcinoma, we performed global gene analysis
of DNA copy number changes in selected tumor cells
sampled from a chemotherapy-resistant bone marrow
metastasis. The gene analysis showed amplification of
Figure 4 Biopsies obtained from the primary oesophageal
tumor, liver metastasis and right iliac bone metastasis of the
35-year-old male at the time of diagnosis, and from a
corresponding right iliac bone metastasis after three cycles of
chemotherapy. (A) Hematoxylin and eosin (HE) staining of the
primary oesophageal tumor and corresponding
immunohistochemical c-erbB2 staining (brown) of the same biopsy
(B-D), where both positive and negative tumor cells are seen (C). (B)
A close-up of C showing erbB2 negative tumor cells. (D) A close-up
of C showing erbB2 positive tumor cells. (E) HE staining of a bone
biopsy sampled at the time of diagnosis. (F) erbB2 staining of the
same bone biopsy as E, showing only weakly positive staining (1+)
and termed clinically negative. (G) HE staining of a liver metastasis
biopsy. (H) erbB2 staining of the same liver metastasis biopsy,
showing only weakly positive staining (1+) and termed clinically
negative. (I) HE staining of a biopsy from bone metastasis of the
right iliac bone sampled after three cycles of chemotherapy. (J)
erbB2 immunohistochemical staining of the same biopsy as I,
showing bone marrow infiltrated with tumor cells strongly positive
(3+) for erbB2.
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KRAS and ERBB2 oncogenes as possible molecular tar-
gets of therapy in tumor cells. However, after the dis-
continuation of EOX therapy, erbB2 targeted therapy
with trastuzumab monotherapy was unable to provide
substantial disease control, since his general health con-
dition deteriorated rapidly. Other factors in addition to
erbB2 receptor expression and signaling could also be
important to sustain disease progression. In the case of
cetuximab treatment of colorectal cancer, which targets
another receptor of the ERBB-family (the epidermal
growth factor receptor) the expression of receptor
ligands (i.e. amphiregulin and epiregulin), as well KRAS
mutation, predict treatment response [16]. For our
patient, we did not detect any mutation in the KRAS
gene, but amplification of the gene was detected. Poten-
tially, high expression of the GTPase Kras oncoprotein,
due to gene amplification, could sustain oncogenic sig-
naling despite erbB2 inhibition by trastuzumab treat-
ment. Other mechanisms of trastuzumab resistance
could also be involved [17]. Immunohistochemical
Figure 5 ERBB2 and KRAS gene amplification. Open arrows indicate examples of non-amplified cells, whereas closed arrows point to cells
with gene amplification. Images were taken with a Zeiss Axioplan 2 fluorescence microscope objective ×60. (A) Fluorescence in situ
hybridization of the ERBB2 gene (red) in the primary gastroesophageal tumor shows amplified signals as compared to the reference centromere
17 (green). (B) FISH analysis of ERBB2 (red) and centromere 17 (green) in an iliac bone metastasis progressing during chemotherapy. (C) FISH
analysis of the KRAS gene (red) and centromere 12 (green) in the primary gastroesophageal tumor. (D) FISH analysis of KRAS (red) and
centromere 12 (green) in an iliac bone metastasis progressing during chemotherapy. One positive cell is displayed at ×2,5 higher magnification
than cells in A-C. Blue color indicates DAPI nuclear counterstaining.
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analysis showed heterogeneous expression of erbB2,
with distinct erbB2-positive tumor cell populations
before chemotherapy in the primary tumor, but negative
cells in the liver and bone marrow, with cells staining
strongly positive for erbB2 in bone marrow after the
three initial cycles of chemotherapy. These results were
furthermore supported by the finding of a similar pat-
tern for ERBB2 gene amplification, as shown by the
FISH results. Heterogeneous gene amplification was
found both for the ERBB2 and the KRAS genes, but par-
ticularly enrichment of ERRB2 amplified cells was found
in the biopsy from the bone metastasis after the initial
three courses of chemotherapy. The clinically validated
c-erbB2 immunohistochemistry analyses and ERBB2
FISH analyses supported and served as controls for the
array CGH results of ERBB2 gene amplification found
in the tumor cells harvested from the separate bone
marrow aspirate, indicating an enrichment of such cells
in the bone marrow metastasis which clearly progressed
during the initial three courses of chemotherapy as
shown on the computer tomography radiographs. A
decreased sensitivity to the EOX treatment in the
ERBB2 amplified cells could be one explanation for the
enrichment of such cells during chemotherapy.
The patient died 9.5 months after onset of first line
treatment with EOX chemotherapy. Median overall sur-
vival for patients with advanced gastroesophageal cancer
receiving EOX chemotherapy in the REAL2 study was
reported to be 11.2 months [18]. As in breast carcino-
mas, amplification of ERBB2 is found in 20-30% of ade-
nocarcinomas of the esophagus, gastroesophageal
junction and stomach, and is associated with poorer sur-
vival [19,20]. Interventional protocols targeting erbB2 in
gastroesophageal adenocarcinoma have been conducted
[21]. Data from the large phase III ToGA trial was
recently published [22], where stage IV c-erbB2 positive
gastric or esophageal adenocarcinomas were randomized
to receive cisplatin and 5-FU or capecitabine ± trastuzu-
mab, showing a significantly prolonged survival for the
trastuzumab arm. These results have introduced c-erbB2
targeted therapy in the first line treatment for selected
patients with metastatic gastroesophageal adenocarcino-
mas. Among several genetic abnormalities, both KRAS
and ERBB2 amplification have been indicated as early
events in adenocarcinoma development of Barrett’s Eso-
phagus [23]. Amplification of wild-type KRAS has been
implicated in therapy resistance in vitro, but the clinical
importance is yet poorly described. Analysis of aberra-
tions at the molecular level found in each patient’s
tumor cells can identify new therapeutic options. Such
molecular characterization of tumors to identify poten-
tial therapeutic targets has been performed in pilot stu-
dies [24].
Conclusion
Global analysis of genetic aberrations, as illustrated in
this case by performing array-CGH analysis on genomic
DNA from only a few selected tumor cells of interest,
can by way of identifying resistance markers obtain
information on potential therapeutic targets responsible
for malignant progression, as well as potential predictors
of treatment response, thus emphasizing the importance
of this powerful tool on the road to more personalized
cancer therapies in the future.
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